• Something wrong with this record ?

The role of hypoxia-inducible factor 1 in tumor immune evasion

L. You, W. Wu, X. Wang, L. Fang, V. Adam, E. Nepovimova, Q. Wu, K. Kuca

. 2021 ; 41 (3) : 1622-1643. [pub] 20201211

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Hypoxia-inducible factor 1 (HIF-1) plays an indispensable role in the hypoxic tumor microenvironment. Hypoxia and HIF-1 are involved in multiple aspects of tumor progression, such as metastasis, angiogenesis, and immune evasion. In innate and adaptive immune systems, malignant tumor cells avoid their recognition and destruction by HIF-1. Tumor immune evasion allows cancer cells to proliferate and metastasize and is associated with immunotherapy failure and chemoresistance. In the hypoxic tumor microenvironment, HIF-1 signaling suppresses the innate and adaptive immune systems to evade immune attack by inducing the expression of immunosuppressive factors and immune checkpoint molecules, including vascular endothelial growth factor, prostaglandin E2 , and programmed death-ligand 1/programmed death-1. Moreover, HIF-1 blocks tumor-associated antigen presentation via major histocompatibility complex class I chain-related/natural killer group 2, member D signaling. Tumor-associated autophagy and the release of tumor-derived exosomes contribute to HIF-1-mediated immune evasion. This review focuses on recent findings on the potential mechanism(s) underlying the effect of hypoxia and HIF-1 signaling on tumor immune evasion in the hypoxic tumor microenvironment. The effects of HIF-1 on immune checkpoint molecules, immunosuppressive molecules, autophagy, and exosomes have been described. Additionally, the potential role of HIF-1 in the regulation of tumor-derived exosomes, as well as the roles of HIF-1 and exosomes in tumor evasion, are discussed. This study will contribute to our understanding of HIF-1-mediated tumor immune evasion, leading to the development of effective HIF-1-targeting drugs and immunotherapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004415
003      
CZ-PrNML
005      
20220127145253.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/med.21771 $2 doi
035    __
$a (PubMed)33305856
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a You, Li $u College of Life Science, Yangtze University, Jingzhou, China
245    14
$a The role of hypoxia-inducible factor 1 in tumor immune evasion / $c L. You, W. Wu, X. Wang, L. Fang, V. Adam, E. Nepovimova, Q. Wu, K. Kuca
520    9_
$a Hypoxia-inducible factor 1 (HIF-1) plays an indispensable role in the hypoxic tumor microenvironment. Hypoxia and HIF-1 are involved in multiple aspects of tumor progression, such as metastasis, angiogenesis, and immune evasion. In innate and adaptive immune systems, malignant tumor cells avoid their recognition and destruction by HIF-1. Tumor immune evasion allows cancer cells to proliferate and metastasize and is associated with immunotherapy failure and chemoresistance. In the hypoxic tumor microenvironment, HIF-1 signaling suppresses the innate and adaptive immune systems to evade immune attack by inducing the expression of immunosuppressive factors and immune checkpoint molecules, including vascular endothelial growth factor, prostaglandin E2 , and programmed death-ligand 1/programmed death-1. Moreover, HIF-1 blocks tumor-associated antigen presentation via major histocompatibility complex class I chain-related/natural killer group 2, member D signaling. Tumor-associated autophagy and the release of tumor-derived exosomes contribute to HIF-1-mediated immune evasion. This review focuses on recent findings on the potential mechanism(s) underlying the effect of hypoxia and HIF-1 signaling on tumor immune evasion in the hypoxic tumor microenvironment. The effects of HIF-1 on immune checkpoint molecules, immunosuppressive molecules, autophagy, and exosomes have been described. Additionally, the potential role of HIF-1 in the regulation of tumor-derived exosomes, as well as the roles of HIF-1 and exosomes in tumor evasion, are discussed. This study will contribute to our understanding of HIF-1-mediated tumor immune evasion, leading to the development of effective HIF-1-targeting drugs and immunotherapies.
650    _2
$a lidé $7 D006801
650    _2
$a hypoxie $7 D000860
650    12
$a faktor 1 indukovatelný hypoxií $7 D051793
650    12
$a únik nádoru z imunitní kontroly $7 D019139
650    _2
$a nádorové mikroprostředí $7 D059016
650    _2
$a vaskulární endoteliální růstový faktor A $7 D042461
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Wu, Wenda $u MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Wang, Xu $u National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, China
700    1_
$a Fang, Liurong $u State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
700    1_
$a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Wu, Qinghua $u College of Life Science, Yangtze University, Jingzhou, China $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 41, č. 3 (2021), s. 1622-1643
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33305856 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145250 $b ABA008
999    __
$a ok $b bmc $g 1751780 $s 1155564
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 3 $d 1622-1643 $e 20201211 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...